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Abstract 
Enzyme replacement therapy is at present the option of choice for treatment of lysosomal storage diseases. To explore the feasibility of 
lysosomal enzyme production in milk of transgenic animals, the human acid a-glucosidase cDNA was placed under control of the 
ast-casein promoter and expressed in mice. The milk contained recombinant enzyme at a concentration up to 1.5 I.tg/ml. Enzyme 
purified from milk of transgenic mice was internalized via the mannose 6-phosphate receptor and corrected enzyme deficiency in 
fibroblasts from patients. We conclude that transgenically produced human acid a-glucosidase meets the criteria for therapeutic 
application. 
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Transgenic production of therapeutic proteins in mam- 
malian milk can be an attractive strategy to provide low 
cost treatment for rare diseases [1,2]. We have investigated 
whether this strategy, originally designed for the produc- 
tion of secretory proteins, is also suitable for the manufac- 
turing of lysosomal enzymes to be used for enzyme re- 
placement herapy for lysosomal storage diseases. The 
production of human acid a-glucosidase was taken as 
prototype. Deficiency of acid ot-glucosidase (acid maltase; 
EC 3.2.1.3) leads to glycogen storage disease type II (GSD 
II; Pompe disease; acid maltase deficiency), an autosomal 
recessive disorder with an estimated incidence of 1 in 
100000 in the Caucasian population and 1 in 50000 in 
southern China and Taiwan [3]. The disease is clinically 
and genetically heterogeneous. The common clinical fea- 
ture is generalized muscle weakness. In the severe early 
onset cases also the heart is involved. 
A therapy for GSD II is not available yet, but there is 
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optimism about the applicability of receptor-mediated en-
zyme replacement therapy [4-9]. The receptor aimed at is 
the mannose 6-phosphate r ceptor which is crucial for the 
intracellular targeting of most lysosomal enzymes and for 
the endocytosis and lysosomal delivery of exogenous man- 
nose 6-phosphate containing (lysosomal) proteins [10]. In 
the past, we have demonstrated correction of lysosomal 
glycogen storage in cultured fibroblasts and muscle cells 
of GSD II patients after uptake of mannose 6-phosphate 
containing acid a-glucosidase via this receptor [4,5]. 
Moreover, uptake was demonstrated in heart and skeletal 
muscle of mice receiving acid ot-glucosidase intravenously 
[7]. Similarly, administration of mannose 6-phosphate con- 
taining [3-glucuronidase [11] and a-L-iduronidase [12] to 
animals deficient in these enzymes remedied associated 
clinical features. Most of all, we were encouraged by the 
therapeutic efficacy of enzyme replacement therapy for 
Gaucher disease type I aimed at the mannose-receptor [13]. 
Thus, we have set out to develop methods for production 
of human recombinant, mannose 6-phosphate containing, 
acid a-glucosidase [8,9]. 
We present a first evaluation of transgenic production 
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of human mannose 6-phosphate containing lysosomal en- 
zymes in milk. The method takes advantages of an expres- 
sion vector developed to target expression of foreign secre- 
tory proteins to the mammary glands of mice, rabbits, 
sheep, goats and pigs [ 1,2]. For our pilot studies we have 
used mice as model system. 
To obtain lactation-specific expression of a human acid 
cx-glucosidase transgene, we inserted the human acid cx- 
glucosidase DNA [14] in an expression cassette derived 
from the regulatory sequences of the bovine tXst-casein 
gene [15,16]. The 25.5-kb NotI expression module (Fig. 1) 
excised from plasmid pl6,8aglu was microinjected into 
pronuclei of fertilized mouse oocytes (CBA/BrA × 
C57B1/6), according to Hogan et al. and Platenburg et al. 
[16,17]. Using Southern blot analysis of genomic DNA 
prepared from tail biopsies of the newborn mice, 11 trans- 
genie mice were identified. Ten of these founder mice 
transmitted their transgenes in a Mendelian fashion, one 
did not. The copy number of the transgene in the 10 mouse 
lines was estimated to vary from five to twenty, comparing 
the intensities of the hybridization signals on mouse-tail 
DNA-blots using the human acid et-glucosidase eDNA as 
probe (data not shown). 
The presence of human recombinant acid et-glucosidase 
in the milk of transgenic mice was demonstrated with a 
mouse polyclonal antiserum recognizing specifically the 
human and not the murine isoform [18]. Of the ten lines 
tested (Table 1), three were positive (#1672, #1673 and 
#1676). Line # 1672 had the highest activity of 446 nmol 
MU/ml /h  at midlactation, equivalent o 1.5 I~g acid 
e~-glucosidase/ml. Expression levels were not related to 
the copy-number of the transgene, which suggests integra- 
tion site-dependent transcription. In agreement with the 
activity data, human recombinant acid et-glucosidase was 
detected in the milk of lines #1672, #1673 and #1676 by 
immunoprecipitation f llowed by immunoblotting (Fig. 2). 
Panel A shows specifically the human isoforms, whereas 
both human and murine isoforms are shown in panel B. 
Table 1 
The activity of human recombinant acid a-glucosidase in the milk of 
transgenic and non transgenic animals 
Line a-Glucosidase activity a (n) Estimated amount b
(nmol MU/ml /h )  ( ixg/ml) 
1672 446 (5) 1.5 
1673 162 (3) 0.5 
1676 28 (6) 0.09 
others < 20 (21) - 
n.t. < 20 (5) - 
a Milk samples were collected with a hand-made milking apparatus 10 
minutes after subcutaneous injection of 1 unit oxytocin (PitonS, Organon) 
and stored at -20°C until use. The acid ~x-glucosidase activity in the 
milk samples was determined with the artificial substrate 4-methylumbel- 
liferyl-ct-D-glucopyranoside [18]. Milk samples were adjusted to an activ- 
ity of 10 nmol 4 methylumbelliferone (MU)/h in a final volume of 200 
ill, by adding 10 mM sodiumphosphate pH 6.6, containing 0.9% NaCI 
and 1 mg/ml  bovine serum albumin (PBS), and were incubated with 
protein A Sepharose beads (Pharmacia) to pre-absorb immunoglobulins. 
Thereafter, the recombinant acid tx-glucosidase was precipitated with 
antibodies raised in mice and coupled to protein A Sepharose beads, 
precipitating human but not murine acid a-glucosidase. The activity of 
human acid a-glucosidase in the milk was calculated from the activity 
measured on the Sepharose beads with the artificial substrate as described 
[7,18]. b The amount of human acid ct-glucosidase in the mouse milk was 
calculated based on a specific enzyme activity of 300 i~mol MU/mg/h  
[19]. (n): number of milk samples; others: includes transgenic lines 
#1671, 1675, 1677, 1678, 1679, 1680 and 1692; n.t.: non-transgenic 
lines. 
The human acid c~-glucosidase in the mouse milk is 
present in two isoforms with an apparent molecular mass 
of 110 and 76 kDa, like the precursor and mature forms of 
acid e~-glucosidase present in human tissues. The murine 
isoforms are 95 and 73 kDa (Fig. 2B). 
Expression of the human acid a-glucosidase transgene 
was mammary gland-specific and lactation-dependent as 
illustrated in Fig. 3 for the mammary gland, spleen, heart 
and skeletal muscle. Also no expression of the transgene 
was detected in liver, kidney, brain, lacrimal glands, sali- 
ATG TAG pA 
Not I Cla I EcoRI Sphl Xhol/Sall Not I 
Fig. 1. Physical map of the 25.5 kb mammary gland-specific expression module for human acid ot-glucosidase. To make this module, the acid 
cx-glucosidase eDNA was excised from 2pSHAG2 [14] with EcoRI and SphI and subcloned in pKUN7AC, a pKUN1 derivative [22]. From this plasmid the 
3.3-kb eDNA-fragment was excised with ClaI and XhoI and inserted into the ClaI site and XhoI-compatible SalI site of the plasmid pl6,8hlf3ks 
replacing the lactoferrin eDNA [16]. The resulting plasmid pl6,8ctglu consists of the human acid a-glucosidase eDNA flanked upstream by 14.2 kb of 
sequences, containing the promoter and untranslated first exon of the bovine Ctsn-casein gene, and a hybrid Ctsl-casein/immunoglobulin G intron [23]. The 
eDNA is flanked downstream by 8 kb of 3' bovine c~sl-casein sequences including the polyadenylation signal. Black boxes represent non-translated bovine 
asl-casein exons. Other bovine asrCasein sequences are indicated with a bold line. The hatched line and box represent immunoglobulin G intron and 
exon sequences. The open box represents he human acid tx-glucosidase eDNA. The transcription i itiation site (flag), the translational start site (ATG), the 
stop codon (TAG), and the polyadenylation site (pA) are indicated. 
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Fig. 2. Immunoblot analysis of acid cx-glucosidase from milk of trans- 
genic mice. The milk samples were adjusted to an acid c~-glucosidase 
activity of 100 nmol MU/h in a final volume of 1 ml by adding 10 rmM 
PBS and were cleared of immunoglobulins ( ee the legend of Table l for 
details). Acid c~-glucosidase was subsequently precipitated with antibod- 
ies raised against human placental acid o~-glucosidase complexed to 
protein A Sepharose beads. The Sepharose beads with the enzyme-im- 
munoglobulin complex bound to it were boiled in sample buffer and 
applied to SDS-PAGE as described [19]. The proteins were subsequently 
blotted onto nitrocellulose filters and acid ~-glucosidase was visualized 
on X-ray film after incubating the blots with rabbit anti-human placental 
acid c~-glucosidase antibodies coupled to J:SI-protein A. Acid c~-gluco- 
sidase purified from human urine (110 kDa) and human placenta (76 and 
70 kDa) served as molecular mass markers. Panel A shows the human 
acid cx-glucosidase i oforms immunoprecipitated with antibodies raised in 
mouse, not recognizing the mouse isoforms. Panel B shows both the 
human and the mouse isoforms immunoprecipitated with antibodies 
raised in rabbit, recognizing the human as well as the murine acid 
c~-glucosidase isozymes. The numbers above the lanes refer to the 
transgenic lines from which the samples were taken; n.t. is a sample from 
a non-transgenic mouse. The non-expressing lines were chosen randomly. 
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F ig .  3. Immunoblot analysis of tissue and lactation-specific expression of 
the human acid c~-glucosidase transgene. Various tissues from a lactating 
(8 days post-partum) (+) and a non lactating ( - )  mouse of line #1672 
were homogenized as described [7], and the human acid cx-glncosidase 
isoforms were immunoprecipitated with antiserum raised in mice against 
human placental acid c~-glucosidase s described in the legends of Fig. 2. 
Acid ~x-glucosidase purified from human placenta was applied in the first 
lane (M) to serve as molecular mass marker. 
Table 2 
Uptake of acid cx-glucosidase purified from the milk of transgenic mice 
by enzyme-deficient fibroblasts 
Celline Additions M6P Acid ~-glucosidase activity (n) 
enzyme (nmol MU/mg/hr) 
Normal - - 145 (12) 
Deficient - - < 0.1 (4) 
Deficient + - 676 (8) 
Deficient + + 5.5 (4) 
Acid ~-glucosidase was isolated from the milk of transgenic mice. The 
enzyme was added to the culture medium of enzyme deficient fibroblasts 
in a concentration equivalent to 1.4 p~mol MU/h in 1 ml of Ham's FI0 
medium supplemented with 10% fetal bovine serum, 3 mM PIPES and 
antibiotics (as described [24]), in the presence or absence of 5 mM 
mannose 6-phosphate (M6P). The cells were harvested after 22 h and 
homogenized. The acid ~x-glucosidase activity was determined with the 
artificial substrate 4-methylumbelliferyl-¢x-D-glucopyranoside. Protein 
concentrations were determined using the BCA protein assay (Pierce). 
(n) = number of assays. 
vary glands, and lung (data not shown). The molecular 
mass of  the recombinant enzyme in the mammary gland is 
the same as of  mature lysosomal acid e~-glucosidase in
human tissues (76 kDa). All transgenic mice appeared 
healthy and reproduced normally. 
To test the applicabil ity of the recombinant acid cx-glu- 
cosidase for enzyme replacement therapy, the enzyme was 
purified from transgenic mouse milk, essentially as de- 
scribed before [19], and added to culture medium of acid 
c~-glucosidase deficient fibroblasts. Table 2 shows that the 
acid c~-glucosidase activity of the deficient fibroblasts 
increased above control level after overnight incubation. 
Endocytosis was mediated by the mannose 6-phosphate 
receptor, since no corrective ffect was obtained when the 
milk enzyme was administered in the presence of 5 mM 
mannose 6-phosphate. 
In conclusion, the human recombinant acid o~-gluco- 
sidase produced in the mammary gland of transgenic mice 
exhibits the proper characteristics for use in enzyme re- 
placement herapy for GSD II and is an alternative for 
enzyme production in CHO-cel ls  [8,9], It is obvious, how- 
ever, that higher expression levels of  the recombinant 
enzyme in milk are needed for the industrial production of 
therapeutic enzyme. A way to increase the expression level 
is to use genomic rather than cDNA constructs [20]. Our 
prel iminary results indicate that the expression can be 
upgraded by at least 100-fold by using a genomic construct 
[21]. We are encouraged to fully explore the possibilities to 
produce mannose 6-phosphate containing lysosomal en- 
zymes in the milk of transgenic animals for treatment of 
lysosomal storage disease. 
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